SCHEMBL4331457

SCHEMBL4331457

CC1CCCC(N2CCCC2=O)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MGLL Q99685 1/20 0.35
USP2 O75604 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
TSHR P16473 1/20 0.34
KDM5A P29375 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34
MAPK1 P28482 1/20 0.33
AKR1C3 P42330 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17406830 0.87 CHRNB2 (0.38) BRD4BRD2NOS3NOS1ALDH1A1
SCHEMBL11842283 0.82 NOS3 (0.45) BRD4BRD2NOS3NOS1MGLL
SCHEMBL21739122 0.79 RAB9A (0.34) NOS3NOS1CHRNB2CHRNB4CHRNA3
SCHEMBL19276941 0.79 RAB9A (0.34) NOS3NOS1CHRNB2CHRNB4CHRNA3
SCHEMBL21740357 0.79 RAB9A (0.34) NOS3NOS1CHRNB2CHRNB4CHRNA3
SCHEMBL5949581 0.79 ADORA2A (0.40) BRD4BRD2TSHRKDM5AAKR1C3
SCHEMBL13515773 0.79 ADORA2A (0.40) BRD4BRD2TSHRKDM5AAKR1C3
SCHEMBL24065150 0.79 JAK2 (0.34) BRD4BRD2NOS3NOS1MGLL
SCHEMBL5500624 0.79 KDM5A (0.34) BRD4BRD2NOS3NOS1MGLL
SCHEMBL10007403 0.79 JAK2 (0.34) BRD4BRD2NOS3NOS1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612216-B2 Utilizing metal catalyst; one step; low cost E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-11-03 US disclosed
EP-1613573-A4 PRODUCTION OF 5-METHYL-1-HYDROCARBYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID DU PONT (US) 2008-10-29 EP disclosed
EP-1605934-A4 PRODUCTION OF 5-METHYL-N-(METHYL ARYL)-2-PYRROLIDONE, 5-METHYL-N-(METHYL CYCLOALKYL)-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE DU PONT (US) 2008-10-08 EP disclosed
EP-1606252-A4 PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYL CYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYCYANO COMPOUNDS DU PONT (US) 2008-08-06 EP disclosed
EP-1605933-A4 PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES DU PONT (US) 2008-07-02 EP disclosed
EP-1606253-A4 PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEUVLINIC ACID ESTERS WITH NITRO COMPOUNDS DU PONT (US) 2008-03-05 EP disclosed
EP-1605754-A4 PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH NITRO COMPOUNDS DU PONT (US) 2008-03-05 EP disclosed
EP-1605755-A4 PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS DU PONT (US) 2008-02-27 EP disclosed
US-7129362-B2 Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-10-31 US disclosed
CN-1764378-A Reductive amination of lactones with arylamines to produce N-aryl-2-lactams and N-cycloalkyl-2-lactams DU PONT (US) 2006-04-26 CN disclosed
WO-2004084887-A1 PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2004-10-07 WO disclosed
US-20040192936-A1 PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192932-A1 Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds E.I. DU PONT NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192937-A1 PRODUCTION OF N-ARYL-2-LACTAM AND N-CYCLOALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AMINES E. I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192939-A1 Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines MANZER LEO ERNEST (US) 2004-09-30 US disclosed
US-20040192935-A1 Production of 5-methyl-N-(methyl aryl)-2-pyrrolidone, 5-methyl-N-(methyl cycloalkyl)-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with cyano compounds E.I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192934-A1 Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with nitro compounds E. I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192938-A1 Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines E. I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-20040192933-A1 Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid E.I. DU PONT DE NEMOURS AND COMPANY 2004-09-30 US disclosed
US-6743819-B1 METAL CATALYST E. I. DU PONTE DE NEMOURS AND COMPANY 2004-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192934-A1 Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with nitro compounds PNPO, ALDH18A1, NLN BRD4 2612/4885BRD2 2196/4885NOS3 137/4885
US-20040192933-A1 Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid ALDH18A1, PRMT5, PYCR1 BRD4 2833/4885BRD2 1942/4885NOS3 2319/4885
US-20040192939-A1 Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines PNPO, ASNS, PAH BRD4 3320/4885BRD2 2724/4885NOS3 1287/4885
US-20040192937-A1 PRODUCTION OF N-ARYL-2-LACTAM AND N-CYCLOALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AMINES NIT2, AAAS, ASNS BRD4 843/4885BRD2 322/4885NOS3 416/4885
US-20040192936-A1 PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS NIT2, NANS, ASNS BRD4 936/4885BRD2 565/4885NOS3 149/4885
US-20040192938-A1 Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines PAH, ALDH18A1, PNPO BRD4 1720/4885BRD2 1332/4885NOS3 1598/4885
US-20040192932-A1 Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds AAAS, ASNS, NIT2 BRD4 889/4885BRD2 395/4885NOS3 792/4885
US-20040192935-A1 Production of 5-methyl-N-(methyl aryl)-2-pyrrolidone, 5-methyl-N-(methyl cycloalkyl)-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with cyano compounds PNPO, ALDH18A1, RIMKLA BRD4 2814/4885BRD2 1820/4885NOS3 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.